C
Claritas Pharmaceuticals Inc
XTSX:CLAS
Claritas Pharmaceuticals Inc
XTSX:CLAS
Price:
0.295
CAD
Market Cap:
CA$10.4m
Relative Value
There is not enough data to reliably calculate the relative value of CLAS.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CLAS
Relative Value
Base Case
Not Available
C
Multiples Across Competitors
CLAS Competitors Multiples
Claritas Pharmaceuticals Inc Competitors
Claritas Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
C
|
Claritas Pharmaceuticals Inc
XTSX:CLAS
|
10.4m CAD | 0 | -1.6 | 15.5 | 15.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
879B USD | 13.2 | 41.7 | 28.2 | 30.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
573.4B USD | 6.1 | 21.5 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
257.8B CHF | 4.2 | 20 | 11.8 | 13.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
220.5B GBP | 5 | 28.8 | 16 | 22.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
231.4B CHF | 5.2 | 21 | 13 | 16.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.7B USD | 4.4 | 15.5 | 9.6 | 11.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
240.1B USD | 103.6 | -82.1 | 380.1 | 953.2 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.1B USD | 2.5 | 19.9 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.2B USD | 2.5 | 17 | 7.2 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
